Revised forecast
Fiscal year ending March 2026 · Full year (1 April 2025 to 31 March 2026)Previous forecast published Announced on 9 February 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Operating profit exceeded the forecast due to the higher sales mix of films for the high-margin medical sector and industrial materials, reductions in raw material and energy costs, expense controls, and the promotion of price revisions. Ordinary profit exceeded the forecast due to foreign exchange gains resulting from the weaker yen and the recognition of equity in earnings from investments accounted for under the equity method, among other factors. Although an extraordinary loss was recorded, net income also exceeded the forecast.
Consolidated: impairment loss of ¥905 million. Non-consolidated: impairment loss of ¥905 million and valuation loss on shares of affiliated companies of ¥674 million.
| Item | Details |
|---|---|
| Net Sales | ¥81,000 million → ¥81,802 million（+1.0%） |
| Operating profit | ¥2,300 million → ¥2,972 million（+29.3%） |
| Ordinary income | ¥2,550 million → ¥3,919 million（+53.7%） |
| Profit attributable to owners of the parent | ¥1,450 million → ¥2,116 million（+46.0%） |
| Net income per share | 106.1 yen and sen → 154.87 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year (1 April 2025 to 31 March 2026) |
| Publication date of previous forecast | Announced on 9 February 2026 |
| Previous-period results | Consolidated: net sales of ¥79,093 million, operating loss of ¥436 million, ordinary loss of ¥220 million, profit attributable to owners of parent of ¥427 million, and earnings per share of ¥30.67. Non-consolidated: net sales of ¥62,705 million, operating profit of ¥554 million, ordinary profit of ¥1,322 million, net income of ¥1,514 million, and earnings per share of ¥108.56. |
| Reason for the revision | Operating profit exceeded the forecast due to the higher sales mix of films for the high-margin medical sector and industrial materials, reductions in raw material and energy costs, expense controls, and the promotion of price revisions. Ordinary profit exceeded the forecast due to foreign exchange gains resulting from the weaker yen and the recognition of equity in earnings from investments accounted for under the equity method, among other factors. Although an extraordinary loss was recorded, net income also exceeded the forecast. |
| Details and amount of extraordinary loss | Consolidated: impairment loss of ¥905 million. Non-consolidated: impairment loss of ¥905 million and valuation loss on shares of affiliated companies of ¥674 million. |
| Dividend forecast revision | The year-end dividend has been increased by ¥10, from ¥30.00 to ¥40.00 per share. Total dividends amount to ¥546 million. |
| Consolidated / non-consolidated | Consolidated / non-consolidated (standalone) |
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Operating profit exceeded the forecast due to the higher sales mix of films for the high-margin medical sector and industrial materials, reductions in raw material and energy costs through consolidated production and other measures, expense controls, and the promotion of price revisions. Ordinary profit also exceeded the forecast, mainly due to foreign exchange gains resulting from the weaker yen. The dividend was increased based on the policy of stable profit returns and the Company's performance.